Close

Amgen (AMGN): No Conclusion on Sensipar's Role in Death, Still Working with FDA

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/16/2024

1. SPY
2. TSLA
3. AMD
4. JNJ
5. ITCI
6. GS
7. BAC
8. MS
9. BK
10. UNH


Go back to Amgen (AMGN): No Conclusion on Sensipar's Role in Death, Still Working with FDA

NPS Pharmaceuticals (NPSP) On Watch on Amgen (AMGN) Sensipar News

February 26, 2013 12:12 PM EST

NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) is on watch on news the FDA has stopped all pediatric clinical trials of Amgen's (Nasdaq: AMGN) Sensipar after the recent death of a 14-year-old patient in a trial.... More

Trials of Amgen's (AMGN) Sensipar Halted Following Death - FDA

February 26, 2013 12:01 PM EST

The U.S. Food and Drug Administration (FDA) has stopped all pediatric clinical trials of Amgen's (Nasdaq: AMGN) Sensipar (cinacalcet hydrochloride) after the recent death of a 14-year-old patient in a trial. FDA continues to gather information on the circumstances surrounding the patients death. Sensipar is a medication used to decrease the release of parathyroid hormone (PTH) from the parathyroid gland. Sensipar lowers high PTH levels leading to lower calcium levels in the blood; when calcium levels are too low it can result in health problems. FDA has approved Sensipar for use... More